The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a more substantial loss in body mass and improve metabolic health, particularly co